Tadalafil oral film - IntelGenx

Drug Profile

Tadalafil oral film - IntelGenx

Alternative Names: INT-007; INT0007; INT0007/2006; Tadalafil - IntelGenx; Tadalafil film - IntelGenx

Latest Information Update: 29 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IntelGenx Corp.
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Pyridones; Small molecules; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Erectile dysfunction

Most Recent Events

  • 22 Oct 2018 IntelGenx Technologies announces intentions for 505(b) submission with the US FDA (9509)
  • 18 Oct 2018 Phase-I development is ongoing in USA
  • 18 Oct 2018 Discontinued - Phase-I for Erectile dysfunction (In volunteers) in Canada (PO) (IntelGenx website, October 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top